Day One Biopharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $206,064,000.
Profit Margin
| 2019 | 0 | -14.71M | |
|---|---|---|---|
| 2020 | 0 | -40.50M | |
| 2021 | 0 | -70.44M | |
| 2022 | 0 | -132.17M | |
| 2023 | 0 | -188.91M |
DAWN Income Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Revenue | |||||
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 383K | 531K | 199K | 155K | 0 |
Gross profit | -383K | -531K | -199K | -155K | 0 |
Operating exp. | |||||
Research and development | 130.52M | 85.61M | 43.58M | 9.1M | 13.89M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 206.06M | 146.90M | 72.74M | 13.78M | 14.90M |
Operating income | -206.06M | -146.90M | -72.74M | -13.78M | -14.90M |
Other income (expenses), net | 17.14M | 4.72M | -11K | -30.06M | -2.07M |
Income before tax | -188.91M | -142.18M | -72.75M | -43.84M | -16.98M |
Income tax expense | 0 | -10.00M | -2.31M | -3.33M | -2.27M |
Net income | -188.91M | -132.17M | -70.44M | -40.50M | -14.71M |
Earnings per share | |||||
Basic EPS | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
Diluted EPS | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
| Data source | Data source | Data source |